眶内容物摘除术在II至IV期眼睑皮脂腺癌中的价值:78例患者队列研究
该回顾性单中心研究纳入78例眼睑皮脂腺癌患者,其中II期60例(76.9%)、III期13例(16.7%)、IV期5例(6.4%),中位随访40.5个月。II期患者经倾向性评分匹配(1:3)后,保留眼球治疗与眶内容物摘除术预后相当;累及赤道区的肿瘤推荐行眶内容物摘除术。
要点
- II期眼睑皮脂腺癌中,保留眼球治疗与眶内容物摘除术的预后相当。
- 肿瘤累及赤道区时,推荐行眶内容物摘除术。
- 出现远处转移的患者,全身治疗可能有益,但尚需进一步研究优化辅助治疗。
核心结论
- II期眼睑皮脂腺癌中,保留眼球治疗与眶内容物摘除术的预后相当。
- 肿瘤累及赤道区时,推荐行眶内容物摘除术。
- 出现远处转移的患者,全身治疗可能有益,但尚需进一步研究优化辅助治疗。
研究设计与样本
- 回顾性单中心队列研究,纳入78例眼睑皮脂腺癌患者。
- II期患者中,对接受眶内容物摘除术与接受保留眼球治疗者按1:3进行倾向性评分匹配(PSM)。
- 对保留眼球治疗组采用Cox回归分析危险因素,并用Kaplan-Meier法评估无转移生存(MFS)、无复发生存(RFS)、疾病特异性生存(DSS)和无进展生存(PFS)。
主要发现
- 78例患者来自上海交通大学医学院附属第九人民医院,2010年1月至2024年7月收治,中位随访40.5个月。
- II期60例(76.9%),III期13例(16.7%),IV期5例(6.4%)。
- 倾向性评分匹配后,临床T分期较晚(cT4 vs. cT3)或累及赤道区的患者更可能需要眶内容物摘除术,且保留眼球手术后MFS更差。
- II期死于肿瘤相关原因的患者平均生存144.3个月。
- III期远处转移患者转移后平均生存12.5个月;IV期患者从诊断到肿瘤特异性死亡平均49.0个月。
关键数值与推荐
- II期眼睑皮脂腺癌:保留眼球治疗与眶内容物摘除术预后相当。
- 肿瘤累及赤道区:推荐行眶内容物摘除术。
- 远处转移患者:全身治疗可能有益,但尚需进一步研究优化辅助治疗。
临床怎么用
- II期眼睑皮脂腺癌可考虑保留眼球治疗,其预后与眶内容物摘除术相当。
- 肿瘤累及赤道区时,推荐行眶内容物摘除术。
- 出现远处转移的患者,全身治疗可能有益,但尚需进一步研究优化辅助治疗。
局限性
- 本研究为回顾性、单中心研究。
- 全身治疗对远处转移患者可能有益,但尚需进一步研究以优化辅助治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the prognosis of eyelid sebaceous carcinoma (SeC) in patients with disease stage worse than IIA. METHODS: This retrospective, single-center study included 78 SeC patients. For stage II patients, 1:3 propensity score matching (PSM) was applied between those undergoing orbital exenteration and those receiving eye-sparing treatments. Risk factors in the eye-sparing group were analyzed using Cox regression, and Kaplan-Meier survival analysis assessed metastasis-free survival (MFS), recurrence-free survival (RFS), disease-specific survival (DSS), and progression-free survival (PFS). RESULTS: Seventy-eight patients treated at Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, from January 2010 to July 2024, were followed for a median of 40.5 months. Of these, 60 patients (76.9%) had stage II disease, 13 patients (16.7%) had stage III, and five patients (6.4%) had stage IV. After PSM, patients with an advanced clinical T (cT) category (cT4 vs. cT3) or equatorial region involvement were more likely to require orbital exenteration and had poorer MFS following eye-sparing surgery. For stage II patients who died of tumor-related causes, the average survival was 144.3 months. For stage III patients with distant metastasis, survival post-metastasis averaged 12.5 months; for stage IV patients, the time from diagnosis to tumor-specific death averaged 49.0 months. CONCLUSIONS: In stage II SeC, eye-sparing treatment offered comparable outcomes to orbital exenteration. Orbital exenteration is recommended for tumor involved with the equatorial region. Systemic therapy may be beneficial for patients with distant metastases, although further research is needed to optimize adjuvant treatment.
引用
- Chen J, Zhu T, Huang Z, et al. The Value of Orbital Exenteration for Eyelid Sebaceous Carcinoma in Stages II to IV: A Cohort Study of 78 Patients. Invest Ophthalmol Vis Sci. 2025. PMID: 39821000. doi:10.1167/iovs.66.1.40
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。